PolyPid Ltd.
PYPD Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$5.77
KIRA · Stoqly’s AI analyst, in plain words
- PolyPid Ltd. lost $34.2M in fiscal 2025. From fiscal 2018 to 2025, diluted EPS grew 13.5% a year.
- Free cash flow was −$28.1M in fiscal 2025, — of revenue.
- PolyPid Ltd. has $5.4M more cash than debt.
Market cap
$94.4M
P/E
2.8x
Revenue
—
Net income
−$34.2M
Free cash flow
−$28.1M
Operating margin
—
PolyPid Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$34.2M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
2.8x
One share costs 2.8 times its yearly profit per share.
What PolyPid Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 25, 2026
- Legal name
- PolyPid Ltd.
- CIK
- 0001611842
PolyPid Ltd. · PYPD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$42.6M | −$39.6M | −$23.9M | −$29.0M | −$34.2M |
| Diluted EPS | $68.27 | $61.09 | $16.93 | $4.91 | $2.09 |
| Cash | |||||
| Cash from operations | −$32.4M | −$34.3M | −$17.2M | −$22.0M | −$27.9M |
| Capital expenditure | $2.7M | $1.8M | $0.2M | $0.1M | $0.2M |
| Free cash flow | −$35.0M | −$36.1M | −$17.4M | −$22.0M | −$28.1M |
| Share count change | −93.5% | 3.8% | 119.5% | 316.0% | 176.5% |
| Debt and strength | |||||
| Cash and short-term investments | $9.8M | $8.6M | $5.3M | $15.6M | $6.4M |
| Debt incl. finance leases | — | $11.6M | $10.4M | $7.4M | $1.0M |
| Shareholders' equity | $36.0M | $5.8M | −$2.1M | $7.7M | $11.0M |
| Current ratio | 4.3x | 1.7x | 0.8x | 1.3x | 2.0x |
| Returns and quality | |||||
| Return on capital | — | −346.2% | −606.8% | — | −468.5% |
| Return on equity | −78.4% | −189.3% | −1,278.6% | −1,038.7% | −366.3% |
| Return on tangible equity | 118.5% | 678.6% | — | −377.7% | −311.4% |
| Piotroski F-score | — | — | 1 | 4 | 3 |
| Altman Z'' | −10.9 | −35.3 | −61.2 | −40.6 | −50.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PolyPid Ltd. · PYPD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.77 a share, the company is worth $94.4M: 2.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001611842). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.